Feinberg
Northwestern Medicine | Northwestern University | Faculty Profiles

News Center

  • Categories
    • Campus News
    • Disease Discoveries
    • Clinical Breakthroughs
    • Education News
    • Scientific Advances
  • Press Release
  • Media Coverage
  • Podcasts
  • Editor’s Picks
    • COVID-19
    • Cardiology
    • Cancer
    • Neurology and Neuroscience
    • Aging and Longevity
    • Artificial Intelligence in Medicine
  • News Archives
  • About Us
    • Media Contact
    • Share Your News
    • News Feeds
    • Social Media
    • Contact Us
Menu
  • Categories
    • Campus News
    • Disease Discoveries
    • Clinical Breakthroughs
    • Education News
    • Scientific Advances
  • Press Release
  • Media Coverage
  • Podcasts
  • Editor’s Picks
    • COVID-19
    • Cardiology
    • Cancer
    • Neurology and Neuroscience
    • Aging and Longevity
    • Artificial Intelligence in Medicine
  • News Archives
  • About Us
    • Media Contact
    • Share Your News
    • News Feeds
    • Social Media
    • Contact Us
Home » Drug Shortens Flu Recovery in Vulnerable Patients
Clinical Breakthroughs

Drug Shortens Flu Recovery in Vulnerable Patients

By Will DossJul 20, 2020
Share
Facebook Twitter Email
Michael Ison, MD, MS, professor of Medicine in the Division of Infectious Diseases, professor of Surgery in the Division of Organ Transplantation and a member of the Robert H. Lurie Comprehensive Cancer Center of Northwestern University, was lead author of the study.

Patients with influenza at risk of complications recovered more quickly after early treatment with the drug baloxavir marboxil, according to a study published in The Lancet Infectious Diseases.

The antiviral was previously approved for use in uncomplicated influenza, and the Food and Drug Administration (FDA) recently approved its use in patients at risk of complications.

“Some people think of flu as a benign illness, but I don’t think everybody appreciates how sick you can get and how a medicine can make you feel better, faster,” said Michael Ison, MD, MS, professor of Medicine in the Division of Infectious Diseases and lead author of the study.

Among healthy individuals, the average duration of symptoms is between five and seven days. This often means two to three missed days of work, and raises the possibility of spreading influenza to others in the household.

“Even for someone who’s healthy, these therapies can speed recovery,” said Ison, who is also a professor of Surgery in the Division of Organ Transplantation and a member of the Robert H. Lurie Comprehensive Cancer Center of Northwestern University. “People can miss fewer days of work and get back to their lives.”

However, some patients are at high risk of complications from influenza. Individuals older than 65 with underlying medical conditions or who are overweight could require hospitalization for bacterial or fungal complications such as pneumonia or ear infections, or for cardiovascular conditions such as heart attacks or strokes.

To speed recovery, baloxavir inhibits a polymerase used when the virus copies its RNA, according to Ison.

“It basically prevents the virus from making more viruses,” Ison said.

In the study, investigators enrolled 2,184 patients with influenza-like illness and at least one risk factor for influenza-associated complications. The patients were randomized to receive a placebo, baloxavir or oseltamivir, another antiviral influenza therapy currently in use.

Most years, influenza A accounts for about 80 percent of influenza infections. In this study, nearly half of the patients were diagnosed with influenza A and nearly half with influenza B. This allowed the investigators to test baloxavir’s efficacy against both strains.

They found patients treated with baloxavir experienced quicker recovery and lower viral loads compared to patients treated with the placebo or with oseltamivir for both strains of influenza. Patients with influenza B treated with baloxavir had faster clearance of the virus and quicker clinical recovery than patients treated with oseltamivir or placebo. Patients in the baloxavir group recovered about one day more quickly compared to placebo.

These findings and the recent FDA approval signal that baloxavir should be considered as an early treatment for influenza patients at risk of complications, according to Ison.

This study was sponsored by Shionogi, manufacturer of baloxavir marboxil.

Patient Care Public Health Research
Share. Facebook Twitter Email

Related Posts

Transforming the Way Cancer Vaccines are Designed and Made

Jan 30, 2023

Calcium Channels Regulate Neuroinflammation and Neuropathic Pain 

Jan 27, 2023

Shortage of Mental Health Professionals Linked to Increase in Youth Suicides

Jan 25, 2023

Comments are closed.

Latest News

Medical School Faculty Named AAAS Fellows

Jan 31, 2023

Transforming the Way Cancer Vaccines are Designed and Made

Jan 30, 2023

Calcium Channels Regulate Neuroinflammation and Neuropathic Pain 

Jan 27, 2023

Changes in Medical School Leadership

Jan 26, 2023

Shortage of Mental Health Professionals Linked to Increase in Youth Suicides

Jan 25, 2023
  • News Center Home
  • Categories
  • Press Release
  • Media Coverage
  • Editor’s Picks
  • News Archives
  • About Us
Flickr Photos
Feinberg_In_Vivo_20221209_tcrawford-24
Feinberg_In_Vivo_20221209_tcrawford-16
Feinberg_In_Vivo_20221209_tcrawford-14
Feinberg_In_Vivo_20221209_tcrawford-5
Feinberg_In_Vivo_20221209_tcrawford-6
Feinberg_In_Vivo_20221209_tcrawford-10
Feinberg_In_Vivo_20221209_tcrawford-8
Feinberg_In_Vivo_20221209_tcrawford-18
Feinberg_In_Vivo_20221209_tcrawford
Feinberg_In_Vivo_20221209_tcrawford-23
Feinberg_In_Vivo_20221209_tcrawford-25
Feinberg_In_Vivo_20221209_tcrawford-26

Northwestern University logo

Northwestern University Feinberg School of Medicine

RSS Facebook Twitter LinkedIn Flickr YouTube Instagram
Copyright © 2023 Northwestern University
  • Contact Northwestern University
  • Disclaimer
  • Campus Emergency Information
  • Policy Statements

Type above and press Enter to search. Press Esc to cancel.